Immune Response after the Fourth Dose of SARS-CoV-2 mRNA Vaccine Compared to Natural Infection in Three Doses’ Vaccinated Solid Organ Transplant RecipientsArticle Published on 2022-10-192022-11-15 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] administration analyzed booster booster dose booster doses Breakthrough infection cellular response CLIA Cohort COVID-19 dose Efficacy ELISA ELISpot assay fourth dose General population humoral IgA IgA level IgG immune immune response IMPROVE in both group Infection mRNA mRNA vaccine natural natural infection new SARS-CoV-2 no difference Organ transplant Patient positive recipient recipients repeated response SARS-CoV-2 SARS-COV-2 infection secretion serum IgG severe COVID-19 significant increase significantly increased Solid solid organ transplant Solid organ transplant recipients Still T cell T-cell T-cell Response Transplant vaccination Vaccine vaccine-induced immune response variants of concern [DOI] 10.3390/v14102299 PMC 바로가기
Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancerArticle Published on 2022-10-182022-11-15 Journal: Cell Reports Medicine [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] addition Blood Blood cancer Breakthrough infection Cancer CAPTURE study COVID-19 COVID-19 vaccine Delta detectable dose greater immune response Infection Live virus marker microneutralization NAb titer NAbT Neutralizing Neutralizing antibodies Neutralizing antibody titer of BNT162b2 omicron Patient proportion risk SARS-CoV-2 SARS-CoV-2 variant severe COVID-19 disease T cell response T cells therapy vaccination vaccine dose variants of concern wild-type [DOI] 10.1016/j.xcrm.2022.100781 PMC 바로가기
Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year inReview Published on 2022-10-172023-07-10 Journal: Frontiers in Immunology [Category] COVID19(2023년), [키워드] adverse events COVID-19 Disease modifying therapies immune response multiple sclerosis SARS-CoV-2 Vaccines [DOI] 10.3389/fimmu.2022.1045101 PMC 바로가기 [Article Type] Review
HLA-C dysregulation as a possible mechanism of immune evasion in SARS-CoV-2 and other RNA-virus infectionsArticle Published on 2022-10-172022-11-16 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] alteration Analysis antigenic Cell cells changes in co-morbidities COVID-19 COVID-19 patient COVID-19 patients decrease DNA DNA methylation dysregulation enhancer enhancer transcriptional regulation evade expression Gene Expression gene expression profile genes encoding healthy controls HLA-C Host immune evasion immune response immune system implicated Infection inhibit Intervention involved mechanism memory response Methylation modify overlap Pathogens presenting Prognosis Prognostic marker Protein respiratory infection SARS-CoV-2 shown significantly symptomatic and asymptomatic symptomatic and asymptomatic COVID-19 T-cell therapeutic target transcriptional upper airway upper airways cells. viral antigens virus [DOI] 10.3389/fimmu.2022.1011829 PMC 바로가기
Development of Single-Cell Transcriptomics and Its Application in COVID-19Article Published on 2022-10-162022-11-16 Journal: Viruses [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] acute respiratory distress acute respiratory syndrome application ARDS asymptomatic infection basic reproduction number caused claimed clinical manifestation clinical manifestations component coronavirus coronavirus disease COVID-19 COVID-19 diagnosis COVID-19 research Critical death development differentially expressed gene examined Health immune immune response IMPROVE individual cells mutate offered over physiological resulting SARS-CoV-2 Sequencing single-cell Single-cell transcriptomics syndrome transcriptomics Treatment variety [DOI] 10.3390/v14102271 PMC 바로가기
SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse ModelArticle Published on 2022-10-162022-11-15 Journal: Viruses [Category] COVID19(2023년), SARS, 변종, 치료기술, [키워드] animal model B.1.1.7 B.1.1.7 variant expected greater higher infectivity Human immune system human lung tissue humanized humanized mice immune cells Immune profile immune response Immunity Infection Infectivity lesion Lineage lung lung organoid mice Model mouse no difference overlapping Pathogenesis pathogenesis of SARS-CoV-2 profile replication of SARS-CoV-2 required Research SARS-CoV-2 SARS-COV-2 infection similarity Support supported sustained Th1 Th2 variant variants of concern Viral load viral variant Viral variants virus [DOI] 10.3390/v14102272 PMC 바로가기
Spectral and theoretical study of SARS-CoV-2 ORF10 protein interaction with endogenous and exogenous macroheterocyclic compoundsSARS-CoV-2 ORF10 단백질과 내인성 및 외인성 거대 이종고리 화합물 상호작용에 대한 스펙트럼 및 이론 연구Article Published on 2022-10-152022-09-11 Journal: Spectrochimica acta. Part A, Molecular and biomole [Category] COVID19(2023년), SARS, 치료제, [키워드] Accessory accessory protein accessory proteins Alpha Antiviral approved bind carried caused cells Chlorin choice complexes Compound coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 criteria drug effective drug effective drugs energy Escherichia coli expressed Features form health problem highest affinity Host immune response in silico infected patient infected patients inhibitor inhibitory initial Interaction macrocycle matter modulate molecular docking MOST ORF10 ORF10 protein Orientation pandemic Pathogenesis Porphyrin Pragmatic precedence Protein protoporphyrin public health recommendation resource SARS-CoV-2 SARS-CoV-2 accessory proteins SARS-CoV-2 coronavirus silico studies Spectral Spectroscopy Spectroscopy. Spread Stage suggested Taking the disease the SARS-CoV-2 Treatment treatment of COVID-19 virucidal virus [DOI] 10.1016/j.saa.2022.121403 PMC 바로가기 [Article Type] Article
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics studyArticle Published on 2022-10-142022-11-15 Journal: eLife [Category] COVID19(2023년), SARS, 바이오마커, 진단, [키워드] Abuse Accelerator Antibody Response association Biomarker BNT162b2 characterized clinical trial coronavirus Course COVID-19 COVID-19 patients Critical CXCL10 cytokine dataset develop Disease progression Donor drug early IFN signaling Eiger BioPharmaceuticals enrolled Enrollment heterogeneity Host identify immune immune marker immune response immune signature immunological immunology independent individual Infection Infectious disease Inflammation machine-learning majority marker MCP-3 MCP1 Medicine memory Mild mRNA vaccination natural infection outcome Outpatient outpatients Patient Pfizer-BioNTech plasma plasma protein Post-infection predict Predictive Predictive modeling proteomics provided receiving RIG-I SARS-CoV-2 SARS-CoV-2-infected patients severe symptoms Stanford Stanford University subsequent systems immunology T cell T cell memory the antibody response trajectory transcriptomics Vaccine viral shedding Virological viruses with COVID-19 [DOI] 10.7554/eLife.77943 PMC 바로가기
A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patientsArticle Published on 2022-10-132022-11-15 Journal: Upsala Journal of Medical Sciences [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Abbott anti-S Antigen antivirals BNT162b2 mRNA vaccine Cellular immune response cellular response Chronic kidney disease coronavirus 2 coronavirus disease COVID-19 COVID-19 infection develop dose enrolled evaluated Hemodialysis humoral humoral and cellular immune response. IgG antibody immune response Immunological response ImmunoSpot Infection interquartile range IQR kidney Level median MONITOR monoclonal antibody mRNA pandemic Patient patients positive Protein reactivity respiratory respond robust SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 bnt162b2 mRNA vaccine T-cell T-cell Response the median the Spike the vaccine uremia vaccine dose Vaccines weaker immune response [DOI] 10.48101/ujms.v127.8959 PMC 바로가기
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trialArticle Published on 2022-10-132022-11-15 Journal: eLife [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Activation acute respiratory syndrome antibody approved blood sample Brazil CD4 cellular Chilean China circulating antibodies clinical clinical trial Concentration CoronaVac coronavirus coronavirus disease correlation COVID-19 difference dose Efficacy elicited Emergency use enrolled evaluate evaluated exhibited expression flow cytometry healthy Human humoral immune response humoral immune responses IFN-γ immune response immunization immunogenicity data immunology inactivated Indonesia Inflammation interferon marker Medicine Ministry of Health mononuclear cell multicenter neutralizing antibody neutralizing capacity pandemic PBMCs performed Peripheral blood Phase 3 phase 3 clinical trial phase 3 trial Production progression promote Randomized reported robust Sample SARS-CoV-2 SARS-CoV-2 vaccine secretion separated single center Stimulation T cell Trial Turkey Vaccine Vaccines variants of concern virus VOCs Volunteer were assessed [DOI] 10.7554/eLife.81477 PMC 바로가기